Bellayr Ian H, Catalano Jennifer G, Lababidi Samir, Yang Amy X, Lo Surdo Jessica L, Bauer Steven R, Puri Raj K
Stem Cell Res Ther. 2014 Apr 28;5(2):59. doi: 10.1186/scrt448.
Human multipotent stromal cells (MSCs) isolated from bone marrow or other tissue sources have great potential to treat a wide range of injuries and disorders in the field of regenerative medicine and tissue engineering. In particular, MSCs have inherent characteristics to suppress the immune system and are being studied in clinical studies to prevent graft-versus-host disease. MSCs can be expanded in vitro and have potential for differentiation into multiple cell lineages. However, the impact of cell passaging on gene expression and function of the cells has not been determined.
Commercially available human MSCs derived from bone marrow from six different donors, grown under identical culture conditions and harvested at cell passages 3, 5, and 7, were analyzed with gene-expression profiling by using microarray technology.
The phenotype of these cells did not change as reported previously; however, a statistical analysis revealed a set of 78 significant genes that were distinguishable in expression between passages 3 and 7. None of these significant genes corresponded to the markers established by the International Society for Cellular Therapy (ISCT) for MSC identification. When the significant gene lists were analyzed through pathway analysis, these genes were involved in the top-scoring networks of cellular growth and proliferation and cellular development. A meta-analysis of the literature for significant genes revealed that the MSCs seem to be undergoing differentiation into a senescent cell type when cultured extensively. Consistent with the differences in gene expression at passage 3 and 7, MSCs exhibited a significantly greater potential for cell division at passage 3 in comparison to passage 7.
Our results identified specific gene markers that distinguish aging MSCs grown in cell culture. Confirmatory studies are needed to correlate these molecular markers with biologic attributes that may facilitate the development of assays to test the quality of MSCs before clinical use.
从骨髓或其他组织来源分离出的人类多能间充质干细胞(MSC)在再生医学和组织工程领域具有治疗多种损伤和疾病的巨大潜力。特别是,MSC具有抑制免疫系统的固有特性,目前正在临床研究中用于预防移植物抗宿主病。MSC可以在体外扩增,并具有分化为多种细胞谱系的潜力。然而,细胞传代对细胞基因表达和功能的影响尚未确定。
使用微阵列技术对来自六个不同供体骨髓的市售人类MSC进行基因表达谱分析,这些细胞在相同培养条件下生长,并在第3、5和7代细胞时收获。
这些细胞的表型如先前报道的那样没有变化;然而,统计分析显示有一组78个显著基因在第3代和第7代之间的表达存在差异。这些显著基因均与国际细胞治疗协会(ISCT)建立的用于鉴定MSC的标志物不对应。通过通路分析对显著基因列表进行分析时,这些基因参与了细胞生长、增殖和细胞发育得分最高的网络。对显著基因的文献荟萃分析表明,MSC在广泛培养时似乎正在分化为衰老细胞类型。与第3代和第7代基因表达的差异一致,与第7代相比,MSC在第3代时表现出显著更高的细胞分裂潜力。
我们的结果确定了区分细胞培养中衰老MSC的特定基因标志物。需要进行验证性研究,以将这些分子标志物与生物学特性相关联,这可能有助于开发在临床使用前测试MSC质量的检测方法。